Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

"DEMOS" - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Who May Be Eligible (Plain English)

Who May Qualify: - Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA) - Patients have moderate to severe plaque psoriasis - Patients have signed willing to sign a consent form form (ICF) Who Should NOT Join This Trial: - Simultaneous participation in any interventional study for their moderate-to-severe psoriasis - Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA) * Patients have moderate to severe plaque psoriasis * Patients have signed informed consent form (ICF) Exclusion Criteria: * Simultaneous participation in any interventional study for their moderate-to-severe psoriasis * Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF

Treatments Being Tested

DRUG

Deucravacitinib

According to the product label

Locations (1)

Azienda Ospedaliera Universitaria Integrata Di Verona
Verona, Verona, Italy